Scarica l'app Stockscreener
174.84
4.98%
8.29
Dopo l'orario di chiusura:
174.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Insmed Inc Borsa (INSM) Ultime notizie
Insmed Incorporated (NASDAQ: INSM) Stock Week Ahead: Nasdaq-100 Addition Meets Brensocatib Setback—News, Forecasts, and What to Watch (Dec. 22–26, 2025) - ts2.tech
Nike, Insmed, And Arm Are Among Top 10 Large Cap Losers Last Week (Dec. 15-Dec. 19): Are the Others in Your Portfolio?ARM Holdings (NASDAQ:ARM), BitMine Immersion (AMEX:BMNR), Insmed (NASDAQ:INSM), Lennar (NYSE:LEN) - Benzinga
INSM stock plummets on sinus study failure, adds new pipeline asset - MSN
Voya Investment Management LLC Sells 187,840 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed (BIT:1INSM) Price Target Increased by 16.99% to 218.23 - Nasdaq
The 'worst-case scenario' — why Insmed just reversed after a 181% six-month sprint - MSN
Will Insmed Incorporated (IM8N) stock announce a stock splitPortfolio Performance Summary & Accurate Intraday Trading Signals - ulpravda.ru
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO - RTTNews
What risks investors should watch in Insmed Incorporated stockWeekly Risk Summary & Stock Portfolio Risk Control - ulpravda.ru
Why Insmed Incorporated stock is considered a top pick2025 Bull vs Bear & Detailed Earnings Play Strategies - Улправда
Brinsupri setback slices Insmed market cap — Clinical Report - biocentury.com
Insider Selling: Insmed (NASDAQ:INSM) CEO Sells 10,699 Shares of Stock - MarketBeat
Insmed Insider Sold Shares Worth $1,786,457, According to a Recent SEC Filing - marketscreener.com
INSMED Chair and CEO William Lewis Sells 10,699 Shares - TradingView — Track All Markets
Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next - ts2.tech
Insmed (MIL:1INSM) EV-to-FCF : -35.92 (As of Dec. 19, 2025) - GuruFocus
Insmed (MIL:1INSM) EV-to-OCF : -36.87 (As of Dec. 19, 2025) - GuruFocus
Will Insmed Incorporated (IM8N) stock test record highs in 2025July 2025 Macro Moves & Scalable Portfolio Growth Methods - DonanımHaber
Insmed Delivers ‘Rare Disappointment’ as Brinsupri Flops in Mid-Stage Rhinosinusitis Study - BioSpace
Goldman Sachs reiterates Buy rating on Insmed stock despite trial setback - Investing.com
FY2028 Earnings Estimate for Insmed Issued By HC Wainwright - MarketBeat
Is Insmed Incorporated stock a good choice for value investorsJuly 2025 Fed Impact & AI Enhanced Trading Signals - DonanımHaber
How Insmed Incorporated (IM8N) stock correlates with oil marketsBond Market & Real-Time Volume Analysis Alerts - Улправда
Truist Securities assumes coverage on Insmed stock with Buy rating By Investing.com - Investing.com Canada
Truist Securities assumes coverage on Insmed stock with Buy rating - Investing.com
How Insmed Incorporated stock performs in high volatility markets2025 Retail Activity & Technical Buy Zone Confirmation - DonanımHaber
Insmed Inc : Truist Securities Assumes Covera - 富途牛牛
Will Insmed Incorporated stock remain a Wall Street favoriteJuly 2025 Reactions & Weekly High Conviction Trade Ideas - Улправда
INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset - sharewise.com
Insmed stock price target lowered to $212 by Mizuho after negative study data - Investing.com Australia
RBC Capital Maintains Insmed (INSM) Outperform Recommendation - Nasdaq
HC Wainwright & Co. Maintains Insmed (INSM) Buy Recommendation - Nasdaq
Mizuho's Jared Holz talks Insmed sinking double digits on sinus drug trial news - CNBC
Chmn Lewis Files To Sell 10,699 Of Insmed Inc [INSM] - TradingView — Track All Markets
Biotech, Up 181%, Faces Its 'Worst-Case Scenario' And Dives - Investor's Business Daily
Insmed stock price target lowered to $195 at Leerink on failed trial By Investing.com - Investing.com South Africa
Insmed price target lowered to $203 from $214 at BofA - TipRanks
Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts - ts2.tech
Micron, Insmed among market cap stock movers on Thursday By Investing.com - Investing.com UK
Medical Stocks Worth WatchingDecember 18th - MarketBeat
Micron, Insmed among market cap stock movers on Thursday - Investing.com India
Insmed Stock (INSM) Sinks 18% as Analysts Cut Targets after Trial Failure - TipRanks
INSM: TD Cowen Adjusts Insmed's Price Target Amid Buy Rating | I - GuruFocus
Is Insmed’s 183.7% 2025 Surge Justified by Its Long Term Growth Outlook? - simplywall.st
INSM: Goldman Sachs Lowers Price Target to $225, Maintains Buy R - GuruFocus
Insmed (NASDAQ:INSM) Given New $241.00 Price Target at TD Cowen - MarketBeat
Insmed (INSM) Stock Drops Significantly Amid Market Fluctuations - GuruFocus
INSM: HC Wainwright & Co. Adjusts Price Target, Maintains Buy Ra - GuruFocus
Why Is Insmed Stock Falling Thursday? - Benzinga
Insmed is Now Oversold (INSM) - Nasdaq
Insmed's Pipeline Can Deliver Potential Gains Despite Brensocatib Setback, RBC Says - marketscreener.com
After year of triumph, Insmed stumbles with chronic rhinosinusitis fail, brings in new asset - Endpoints News
High-flying Insmed stumbles with rhinosinusitis trial failure for Brinsupri - Fierce Pharma
Insmed: Managing CRSsNP Setback While Leveraging a Diversified, Innovation-Rich Respiratory Pipeline to Support Buy Rating and $230 Target - TipRanks
Insmed’s ‘win streak’ ends as top drug fails study in chronic nasal condition - BioPharma Dive
Stock Traders Buy Large Volume of Call Options on Insmed (NASDAQ:INSM) - MarketBeat
Insmed (INSM) Stock Drops Over 18% Amid Market Volatility - GuruFocus
Insmed (NASDAQ:INSM) Shares Gap Down on Analyst Downgrade - MarketBeat
Cracking its growth story, Insmed’s nasal inflammation study fails - statnews.com
H.C. Wainwright Maintains Insmed(INSM.US) With Buy Rating, Cuts Target Price to $230 - 富途牛牛
Insmed stock price target lowered to $241 at TD Cowen on missed trial - Investing.com
Mizuho Adjusts Price Target on Insmed to $212 From $256, Maintains Outperform Rating - marketscreener.com
2.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):